嗅神经母细胞瘤的化疗

分析影响嗅神经母细胞瘤化疗的因素并探讨嗅神经母细胞瘤的化疗方案。方法：回顾分析1993年3月至2004年6月收治的4例行化疗的嗅神经母细胞瘤患者的临床资料，包括就诊时年龄、性别、病程、Kadish分期、组织病理学分级、治疗方式、预后，并对文献进行复习。结果：4例均为男性，平均31.5岁，Kadish分期均为C期。组织病理学分级：2级1例，3级2例，4级1例。化疗药物4例含有足叶乙甙、3例含有铂类药物。化疗在首次治疗中应用1例（病理2级随访6个月，带瘤生存），挽救治疗中应用3例（2例病理3级分别随访48个月、6个月无瘤生存，1例病理4级随访12个月带瘤生存）。结论：嗅神经母细胞瘤治疗采用化疗有效，组织病理学分级影响肿瘤对化疗的敏感性，化疗宜采用含铂类及足叶乙甙的多种药物。

Chemotherapy for esthesioneuroblastoma

Objective: To analyze the impact of chemotherapy on esthesioneuroblastoma and illustrate the suitable chemotherapy modality. Methods： A retrospective chart review of patients with esthesioneuroblastoma treated with chemotherapy at our department from Mar. 1993 to Jun. 2004, including age, gender, duration, Kadish staging, Hymas grade,therapy modality and outcome, was analyzed. Results： Four male cases, averagely aged 31.5 years, were treated. All patients were in Kadish C stage, and 1 in Hymas grade 2, 2 in Hymas grade 3, and 1 in Hymas grade 4. The main components of chemical drug included etoposide and platin. Chemotherapy was used as primary therapy on 1 case with grade 2, and the patient was still alive with tumor at the end of follow up of 6 months. Chemotherapy was used on 3 cases as salvage therapy. Among them, 2 cases with grade 3 were alive without tumor after follow ups of 48 months and 6 months respectively, and 1 case with grade 4 was alive with tumor after follow up of 12 months. Conclusions： Adoption of chemotherapy to treat esthesioneuroblastoma is effective, and the Hymas grade of esthesioneuroblastoma affects the response to chemotherapy. The components of chemical drug should include etoposide and platin.